Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question [Seeking Alpha]
Disc Medicine, Inc. (IRON)
Company Research
Source: Seeking Alpha
The FDA requires phase 3 APOLLO data before reconsidering bitopertin approval, delaying any decision until at least mid-2027. IRON's pipeline includes DISC-0974 for myelofibrosis anemia and DISC-3405 for PV and SCD, with key data readouts expected in 2H 2026. With $791 million in cash, IRON is funded into 2029, minimizing near-term dilution risk despite clinical and regulatory uncertainties. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » LordHenriVoton/E+ via Getty Images The last time I spoke about Disc Medicine, Inc. IRON ), it was with respect to a Seeking Alpha article entitled " Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4 [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRONPR Newswire
- Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRONGlobeNewswire
- Disc Medicine (NASDAQ:IRON) was given a new $110.00 price target on by analysts at Stifel Nicolaus.MarketBeat
IRON
Earnings
- 11/6/25 - Miss
IRON
Sec Filings
- 2/19/26 - Form 4
- 2/18/26 - Form 144
- 2/17/26 - Form 4
- IRON's page on the SEC website